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Abstract
Background and Aims: The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic
steatohepatitis (NASH), and progression to cirrhosis. While differences in liver lipids between disease states have been
reported, precise composition of phospholipids and diacylglycerols (DAG) at a lipid species level has not been previously
described. The goal of this study was to characterize changes in lipid species through progression of human NAFLD using
advanced lipidomic technology and compare this with a murine model of early and advanced NAFLD.
Methods: Utilizing mass spectrometry lipidomics, over 250 phospholipid and diacylglycerol species (DAGs) were identified
in normal and diseased human and murine liver extracts.
Results: Significant differences between phospholipid composition of normal and diseased livers were demonstrated,
notably among DAG species, consistent with previous reports that DAG transferases are involved in the progression of
NAFLD and liver fibrosis. In addition, a novel phospholipid species (ether linked phosphatidylinositol) was identified in
human cirrhotic liver extracts.
Conclusions: Using parallel lipidomics analysis of murine and human liver tissues it was determined that mice maintained
on a high-fat diet provide a reproducible model of NAFLD in regards to specificity of lipid species in the liver. These studies
demonstrated that novel lipid species may serve as markers of advanced liver disease and importantly, marked increases in
DAG species are a hallmark of NAFLD. Elevated DAGs may contribute to altered triglyceride, phosphatidylcholine (PC), and
phosphatidylethanolamine (PE) levels characteristic of the disease and specific DAG species might be important lipid
signaling molecules in the progression of NAFLD.
Citation: Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, et al. (2011) Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of
Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model. PLoS ONE 6(8): e22775. doi:10.1371/journal.pone.0022775
Editor: Julio Francisco Turrens, University of South Alabama, United States of America
Received February 28, 2011; Accepted June 30, 2011; Published August 9, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by a large scale consortium grant from the National Institutes of Health U54 GM069338 (to HAB), and 5K08DK0707, and DDRC
award 5P30DK58404 (to DLG). No additional external funding received for this study. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lee.gorden@vanderbilt.edu
. These authors contributed equally to this work.
Introduction
Nonalcoholic fatty liver disease (NAFLD), characterized by
steatosis and progression to steatohepatitis (NASH) and cirrhosis,
is a problem of increasing clinical significance. Statistics in the
United States suggests that 31% of the adult population have
hepatic steatosis [1]. Additionally, obesity is associated with a
number of malignancies including breast and colon carcinomas
[2]. Currently, NAFLD can only be definitively diagnosed by liver
biopsy, but it is suspected in patients with obesity and/or
syndromes of insulin resistance accompanied by elevated serum
aminotransferase levels, commonly referred to as the metabolic
syndrome [3,4].
The detailed composition of the lipids accumulating in NAFLD
is not well characterized on a species level. Lipidomics
technologies permit characterization of lipids in biological systems
at a level previously not possible using traditional methods such as
thin-layer chromatography (TLC), gas chromatography (GC), or
high performance liquid chromatography (HPLC) alone. Prior
reports about the phospholipid distribution in NAFLD have also
shown the importance of the phosphatidylcholine (PC)/phospha-
tidylethanolamine (PE) ratio on liver disease progression from
steatosis to steatohepatitis and its implication as a key regulator of
cell membrane integrity [5]. However, the phospholipid compo-
sition and the redistribution of the increased fatty acids within
specific phospholipid classes as well as important diacylglycerol
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information has more often been studied at the level of total DAG
or by gas chromatography to provide fatty acid specific data rather
than at a lipid species level [6]. Changes in DAG ratios and species
may be important in lipid signaling and in the progression of
NAFLD.
Multiple animal models have been developed to address
metabolism, signaling pathways, and genetic variance that affect
the development of steatosis and steatohepatitis [7,8]. Genetically
modified mice bred for studies in obesity have also been
investigated by mass spectrometry (MS) for species level changes
of DAGs, TAGs, and some phospholipids [9]. Steatosis induced by
high-fat diet is a relevant murine model that we now show reflects
the spectrum of lipid changes associated with human NAFLD.
Application of mass spectrometry techniques in conjunction
with computer assisted analysis [10] has allowed determination of
specific phospholipid and DAG species from liver biopsies and
comparison during disease progression. Defining patterns of
specific lipid species across the spectrum of NAFLD may prove
clinically useful in the early diagnosis and identification of patients
with this disease. Improved insights into lipid signaling pathways
important in progression of NAFLD may also be valuable for
understanding molecular mechanisms involved in disease progres-
sion.
Methods
Ethics Statement
Mice were housed in the accredited animal facility at Vanderbilt
University. Studies were approved by the Vanderbilt Animal Care
and Use Committee (protocol # M/07/262) and every effort to
minimize pain and suffering to the animals was made. Human
tissues were collected under a protocol approved by Vanderbilt’s
Internal Review Board (IRB#: 061257). Biopsies for research
analysis were obtained from clinical biopsy specimens in all cases
and did not require separate consent.
Murine
Eight week old C57bl/6J male mice from Jackson Research
Laboratories were fed a 13.5% fat ‘‘control’’ diet (5001, LabDiet:
13.5% calories from fat, 58% from carbohydrates, and 28.5%
from protein) or a 42% fat ‘‘Western’’ diet (TD.88137, Harlan
Teklad: 42% calories from fat, 42.7% from carbohydrates, and
15.2% from protein) ad libitum for 12 weeks.
Human
Normal human samples were obtained from donor liver biopsies
for liver transplantation. Cirrhotic specimens were recipient livers
during liver transplant. Clinical etiology of cirrhosis was NASH.
Steatotic specimens were obtained from clinical biopsies taken
from morbidly obese patients undergoing gastric bypass surgery.
Patients had no history of ethanol induced steatosis. Three
steatotic samples analyzed had ,10% steatosis on histologic
examination. In spite of mild steatosis in these, the differences
described in the three patient groups remain robust. Specimens
were immediately taken from the operating room and processed
for lipidomics analysis without frozen storage. A portion of the
human samples were used only for phospholipid identification by
tandem mass spectrometry in each condition, while the remainder
were used for global lipid profiling and DAG analysis.
Preparation and Quantitation of Histologic Specimens
Human and murine liver tissue sections were stained with
Hematoxylin for 5 minutes followed by Eosin counterstaining for 1
minute. Quantitation of percent steatosis in human biopsy
specimens was performed in a blinded fashion by pathologists
specializing in liver pathology at Vanderbilt University Medical
Center.
Additionally, Oil red O staining was done using freshly isolated
human and murine liver tissue which was fixed in 10% neutral
buffered formalin at 4uC for two days, transferred to a 20%
sucrose solution for two days and then frozen in Tissue-Tek.
Frozen tissues were sectioned at 8 um on a Microm cryostat set to
219uC and then air dried. In brief, rehydrated liver sections were
stained with Oil red O from 5% stock solution in isopropanol
diluted at 3:2 with distilled water for 20 minutes and counter-
stained with Mayer’s Hematoxylin as previously described [14].
Glycerophospholipid Analysis
Liver biopsies (10–20 mg) were immediately frozen in liquid
nitrogen and phospholipids were extracted as described previously
[11]. Briefly, the frozen samples were placed in a tight-fit glass
homogenizer (Kimble/Kontes Glass Co., Vineland, NJ), 800 mlo f
cold 0.1 N HCl:CH3OH (1:1) was added, and the sample was
homogenized for about 1 min on ice. The suspension was
transferred to a cold 1.5 ml microfuge tube, 400 ml of ice-cold
CHCl3 was added and the extraction proceeded with vortexing
(1 min) and centrifugation (5 min, 4uC, 18, 000 xg) to separate the
layers. The lower organic phase was collected in a new cold
microfuge tube and solvent evaporated under vacuum (Labconco
Centrivap Concentrator, Kansas City, MO). Samples were
redissolved in 80 mlo fC H 3OH:CHCl3 (9:1) and 1 mlo fN H 4OH
(18 M) was added before analysis. Mass spectral analysis was
performed on a Finnigan TSQ Quantum triple quadrupole mass
spectrometer (ThermoFinnigan, San Jose, CA) equipped with a
Harvard Apparatus pump and an electrospray source. Samples
were analyzed at an infusion rate of 10 ml/min in both positive
and negative ionization modes over the range of m/z 350–1200.
Data were collected with the Xcalibur software package
(ThermoFinnigan) and analyzed with software developed in our
laboratory. Identification of individual glycerophospholipids was
accomplished by tandem mass spectrometry (ESI-MS/MS) and
was based on their chromatographic and mass spectral character-
istics [12,15]. This analysis allows identification of the two fatty
acid moieties but does not determine their position on the glycerol
backbone (sn-1 vs. sn-2). Therefore, glycerophospholipid species
are referred to throughout using X:Y notation (X-total number of
carbons, Y-total number of double bonds in both FA, e.g., PE
36:1).
Diacylglycerol Analysis
Frozen samples were homogenized as for the glyceropho-
spholipid analysis and after extraction, diacylglycerols (DAGs)
were separated from more polar phospholipids using a silica gel
column chromatography using isocratic elution with 65:35:0.7 (v/
v/v) CHCl3:CH3OH:H2O and analyzed by mass spectrometry as
sodium adducts as described elsewhere [13].
Data Analysis
Global glycerophospholipid analysis utilized three internal
standards per ionization mode (positive for PCs, negative for all
others). Following normalization, relative peak heights of species
within classes were examined and tables of ratios of intensity
within each class were prepared, similarly to Rouzer et al. [10]
Three replicates were used for each biologically independent
sample. Species-level statistical analysis was performed by
ANOVA (human samples with three conditions) or Student’s t
test (murine samples with two conditions). Quantification and data
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Principal components analysis was carried out in MATLAB.
Results
Clinical samples used for mass spectrometry analysis of human
liver lipids revealed typical histology associated with NAFLD
(Figure 1 panels A–F). Murine samples demonstrated typical
histology of fatty liver disease (Figure 1 panels G–J). For
lipidomic analysis, NAFLD samples were classified as steatotic.
Steatotic specimens showed marked staining with ORO and
various levels of inflammatory infiltrates associated with steatohe-
patitis. Cirrhotic specimens showed characteristic dense fibrosis
and lacked abundant lipid. Similar patterns associated with
steatosis were observed in the livers of mice fed a high fat diet [14].
Clinical characteristics of patients included in normal, steatotic,
and cirrhotic groups are shown in Table 1.
A mass spectrometry lipidomics approach was used to examine
species-specific phospholipid and DAG profiles in human liver
biopsies to assess changes associated with progression of NAFLD.
Glycerophospholipid species were identified within the six major
phospholipid classes (phosphatidylserine PS, phosphatidylinositol
PI, phosphatidylethanolamine PE, phosphatidylcholine PC, phos-
phatidic acid PA, and phosphatidylglycerol PG).
Human Data
To elucidate which lipids were altered in steatotic (NAFLD) and
cirrhotic disease, species-level analysis of phospholipids from
human liver biopsies were compared by ANOVA. This compar-
ison revealed 59 species (out of 154 measured) with significant
changes after applying a Bonferroni correction. Selected species
are depicted in Figure 2. Species of PA changed similarly in
steatotic and cirrhotic when compared to normal controls, with a
clear increase in saturated and monounsaturated fatty acid (FA)
containing PA species in both types of diseased liver samples. The
changes in PG species were also similar in both steatotic and
cirrhotic liver as compared with normal samples, with the greatest
relative difference being an increase in 36:2 PG (primarily
consisting of 18:1/18:1 FA) (28% cirrhotic vs. normal). PS species
showed a different pattern of changes in the two disease stages.
Although several of the polyunsaturated FA (PUFA) containing PS
species (e.g., 40:4 – not shown, 40:5, 40:6) decreased similarly in
both conditions, 38:4 PS increased in steatotic but decreased in
cirrhotic liver. Further, in cirrhotic samples there was an increase
in PS species containing at least one monounsaturated FA, i.e., PS
(36:1, 36:2, 34:1- containing 18:1 FA), while these species either
decreased slightly or did not change in steatotic liver samples. As
with PS, lipid species in the other three major lipid classes, PI, PE,
and PC also showed changes that were distinct in steatotic and
cirrhotic livers. While PUFA-containing PE and PC (e.g., 38:4 –
not shown, 36:4) decreased in cirrhotic samples, saturated, mono-,
and di-unsaturated FA containing PE and PC increased compared
to normal (including PC 34:0 and PE 34:1 which also increase
30%, p,0.001 – data not shown). By contrast, in steatotic liver
samples these same species either remained mostly unchanged or
showed only small changes in the opposite direction. Interestingly,
analysis of PI species did not show any significant differences
between normal and steatotic liver samples. However, in the
cirrhotic samples there was a decrease in the major PUFA-
containing PI (38:4) compared to normal liver while almost all of
the other detected PI species were elevated in this diseased state
compared to normal.
There were differences in PC plasmalogens between disease
states, as PUFA species in the 34:X, 36:X, and 38:X series
increased in the steatotic samples. The overall fraction of the PC
subclass which contained plasmalogen species increased 28% in
the steatotic cases over normal (p,0.001), but did not significantly
increase in the cirrhotic cases as compared to normal. In contrast,
while PE plasmalogens as a group showed less difference between
steatotic and normal samples, several individual PE plasmalogen
species increased more than 33% (e.g., PE 36:4p, 38:4p, 38:5p, all
p,0.05) in the cirrhotic cases as compared to normal.
Overall, a similar number of glycerophospholipid species were
identified in all three human sample types. The number of
identified species differs from the number of species monitored in
the MS analysis as some of them are isobaric or detected at trace
levels. Samples from steatotic and cirrhotic livers appeared to have
more plasmalogen PC species detected than normal (Table S1).
Notably, almost twice as many PS species were identified in
cirrhotic liver samples compared to the normal and steatotic
conditions, which each had a similar number of PS species
represented. One notable difference in cirrhotic livers was the
finding of a rare lipid 38:4 PIe (18:0e, 20:4) which was only
detected in cirrhotic liver samples. Since the presence of ether-PI
in tissues has not been previously reported, the identification was
confirmed by comparison of retention time and fragmentation
spectra to a chemically defined synthetic standard (38:4e PI, 1-
octadecyl-2-(5Z, 8Z, 11Z, 14Z-eicosatetraenoyl)-sn-glycero-3-
phospho-(19-myo-inositol), obtained from Avanti Polar Lipids) as
described elsewhere [15]. (Figure S1)
In addition, analysis also revealed decreases in arachidonic acid-
containing lipid species in the majority of phospholipid classes in
human liver specimens at different disease stages, primarily in
cirrhosis.
Murine Data
Lipid species in livers of mice fed a control (CON) or Western
diet (WD) showed significant changes in 102 (of 147 measured)
lipid species (Bonferroni corrected Student’s t-test). Results are
shown for selected species in each class in Figure 2. Ratiomic
changes were most evident in PC, PS, and PG species when
comparing WD and control samples. Although there were
similarities in how the murine WD/CON lipid profile and the
steatotic/normal human lipid profiles diverged (e.g., particularly
for PS), the mouse WD/CON contrasts bear even stronger
resemblance to the way human cirrhotic livers differed in the
steatotic/normal conditions (manifested mainly within the PS, PI,
and PC classes). There were additional differences in human and
murine profiles. Of note, one species of PI (36:0) was found to
decrease substantially in WD vs. CON samples, but was
completely undetected in human liver samples. Concomitant with
this change, LPI 18:0 increased by 27% (p,0.001) with the high
fat diet over the controls.
Certain lipids showed coherent changes in mice and humans.
Similar to the human liver data, the percentage of the PC subclass
which contained plasmalogen species increased 23% in the WD
mice versus CON (p,0.001), but the fraction of PE plasmalogen
species was unaffected by diet. The portion of the PC class signal
arising from 20:4 fatty acid-containing lipids was also unchanged
in WD versus CON, but this percentage increased in other classes
(PI+20%, PS+31%, both p,0.001) and decreased dramatically in
the primary 20:4 containing PA species, 38:4 (278%, p,0.001).
Changes in Diacylglycerol Levels
Species analysis of TAG precursors, diacylglycerols, demon-
strated multiple fold increases in relatively short chain (30–36
carbon atoms) species containing 0, 1, 2, and 3 double bonds
(Figure 3, Figure 5). The increases were large in human
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the cirrhotic livers. To ensure that the changes observed reflected
strong differences between disease states, the DAG levels were
compared by gender as well. No differences with p,0.01 were
found between genders (data not shown).
Similar analysis of DAGs in murine livers showed large (.4 fold
in ten molecular species) increases with the Western diet versus the
controls. The pattern of DAG changes in the steatotic animals
(WD) was similar to those seen in the human steatotic liver biopsies
with the exception of the 38:X DAGs, which showed no change in
human samples but a modest increase in the murine livers (Figure
4).
Importantly, DAG species analysis in the murine samples
closely resembled the changes in human steatotic livers, but
demonstrated a greater magnitude. Again, the most dramatic
differences were increases in monounsaturated FA–containing
Figure 1. Panels A–F show histological progression of nonalchoholic fatty liver disease in human biopsies. (A,B,C) show hematoxylin
and eosin (H&E) staining, and (D,E,F) show oil red O (ORO) staining. (A,D) normal; (B,E) steatohepatitis; (C,F) cirrhosis. In (A) normal lobular
architecture of the liver is observed, with little fatty change on ORO staining in (D). Changes with progression to steatosis are seen with increased fat
globules. The presence of inflammatory cell infiltrates (B) and lipid droplets are prominently visible in (E). Cirrhotic changes show characteristic
fibrotic pattern (C) and a paucity of staining with ORO in (F). Panels G–J show histology of normal murine liver specimens. (G) H&E staining as well as oil
red O staining (H). Fatty liver disease in murine tissues is histologically demonstrated by H&E (I) and using oil red O staining (J).
doi:10.1371/journal.pone.0022775.g001
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compared to controls.
Principal Components Analysis (PCA) of
Glycerophospholipids reveals distinct profiles by
condition
Compared to the DAGs, there were relatively smaller
magnitude differences in the glycerophospholipids with the disease
state (humans) or diet (mice). For a broad perspective, the
glycerophospholipid profiles of the human liver and mouse liver
were analyzed and compared using eigenanalysis. A plot of the
first three principal eigenvectors of variability for the human data
(Figure 6) showed that the profiles of these lipids inherently
cluster within disease states (normal, steatotic, cirrhotic), validating
that despite a paucity of changes on a lipid species basis (as with
the DAG data), the global profiles between disease conditions were
highly distinct. In particular, the second principal component
efficiently separated the cirrhotic samples from the others based on
their lipid profile, while the first and third principal components
could be used to largely segregate the steatotic and normal
samples. These three principal components together explain 58%
of the variance in the human global lipid data. The ANOVA p-
value comparing the three tissue sample types was significant for
each of the first three principal components (p,0.001). Similar to
the above analysis for DAG with respect to gender, the first two
principal components showed no difference between males and
females, while the third leading component was significant when
comparing genders (p,0.01) but with considerably less contrast
than across disease states (p,1610
25).
PCA of murine global lipids from mice on the two diets (Figure
7) revealed a much less complex profile of variations than in
humans, with the first principal component accounting for 77% of
the variance. For this principal component, the higher-fat
(Western diet) (WD) samples and the normal (CON) samples
were starkly different (Student’s t test, p,1e
26). The decompo-
sition of the data into linearly independent modes of variability via
PCA demonstrated that there are richer modes of variability in
human lipid profiles among the normal and diseased states than
the variability in WD-fed mice versus control-diet mice, which was
rather unidimensional.
Discussion
Mass spectrometric analysis of phospholipids and diacylglycerols
together with computational algorithms can help elucidate
biochemical pathways involved in disease progression. This work
demonstrates the power and reproducibility of lipidomics
techniques in analysis of freshly obtained tissue specimens,
particularly from humans. In addition, this analysis shows the
important potential for lipidomics to characterize progression of
human diseases, in this case NAFLD. Our laboratory has
demonstrated the utility of lipidomics profiling in assessing the
phospholipid composition of macrophages and their remodeling
during zymosan stimulation [10,16], its use for differentiating the
Table 1. Clinical data for sample populations. Patient ages,
body mass index (BMI) and serum liver function tests are
represented as mean values followed by a range in
parentheses.
Normal
(n=12)
NAFLD
(n=17)
Cirrhosis
(n=9)
Female 2 15 2
BMI 23.6 (19.6–33.8) 59 (42.1–85.8)
Age 39.6 (18–62) 40.3 (20–50) 57.8 (49–69)
Serum AST 47.1 (18–64) 30 (16–80) 62.3 (33–110)
Serum ALT 35.8 (18–53) 29 (16–84) 38.6 (16–71)
Histologic
Grade Steatosis
,5–10% 10–80% ,5%
Histologic
Grade Fibrosis
none mild -moderate severe
doi:10.1371/journal.pone.0022775.t001
Figure 2. Selected glycerophospholipid species distribution from human and murine livers. (A, B, C, D, E, F) Data from humans
(represented in graphs on left side of lettered panels)(black bars: normal; open: steatotic; hatched: cirrhotic) for phosphatidic acid (PA),
phosphatidylglycerol (PG), phosphatidylserine (PS) classes, respectively; n=5–9 individuals per group. Graphs on right side of each panel
demonstrate results in mouse model (black bars: control; open: WD); n=3 individual mice per group. Error bars=sem. Asterisks indicate Bonferroni
adjusted significance at better than the *p,0.05, **p,0.01, ***p,0.001 levels from ANOVA across disease states for human data and from Student’s
t test for murine data.
doi:10.1371/journal.pone.0022775.g002
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metabolism [17], and in the study of aging and neurodegenerative
diseases in a mouse model [18].
This study aimed to characterize the phospholipid and DAG
molecular species composition in different stages of NAFLD by
MS profiling. Insights into the abundance, paucity, and relative
Figure 3. Fold changes in diacylglycerol (DAG) species from human livers. Fold changes in DAGs from human steatotic and cirrhotic
samples versus normal samples. All fold changes for steatotic/normal samples in panel A are significant with p,0.05 except for 38:0, 38:1, 38:3, 38:4.
No fold changes for cirrhotic/normal samples in panel A are significant except 38:0,38:1,38:2 (p,0.0122); n=5–9 individuals per group. Error
bars=sem.
doi:10.1371/journal.pone.0022775.g003
Figure 4. Fold changes in diacylglycerol (DAG) species from murine livers. Fold changes (WD/control) in DAGs from murine tissues. All fold
changes in panel B are significant with p,0.024 except for 36:4; n=3 individuals per group.
doi:10.1371/journal.pone.0022775.g004
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into signaling pathways relevant in the progression of NAFLD.
Lipidomics analysis of tissue extracts has been performed, [19–21],
but this study is the first to describe systematic analysis of lipid
composition in human liver extracts using ESI-MS techniques and
to associate the lipidomics results with disease progression. No
prior TLC separation by class and derivatization (for GC-MS
analysis) is needed. This method is faster and more accurate than
previously published and could be used as a high throughput
screening technology. This study is complementary to the results
Figure 5. Fold changes in diacylglycerol (DAG) species from human and murine samples. Comparison between DAG fold changes in
mouse and human liver samples (black bars: human steatotic/normal; gray bars: human cirrhotic/normal; white bars: murine WD/control). All fold
changes for WD/control and steatotic/normal are significant with p,0.0105; none of the fold changes for cirrhotic/normal are significant at p,0.05.
doi:10.1371/journal.pone.0022775.g005
Figure 6. Principal component analysis of human lipidomics data. Human samples for different conditions: normal (dots), steatotic (crosses),
cirrhotic (squares). All replicates are shown.
doi:10.1371/journal.pone.0022775.g006
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account of the fatty acid composition of individual species both in
DAG and phospholipids. The method presented herein allowed
identification of over 200 individual glycerophospholipid species in
each disease state during a single step mass spectrometry analysis.
Without further sample manipulation, differences between plas-
malogen PC and PE content at each step of the disease were
uncovered. Furthermore, the present study has also revealed some
important differences in the phospholipid compositions, such as
the presence of almost twice as many PS species in human
cirrhotic livers compared to normal and steatotic (Table S1). This
method was found sensitive enough to allow for the discrimination
of differences between disease states for within relatively less
abundant lipid classes such as PA, PI, and LPI.
Despite the similar number of glycerophospholipid species
detected in all three human sample types, the number of species
within each class differed considerably (Table S1). Interestingly, a
novel lipid 38:4 PIe (18:0e/20:4) was only detected in cirrhotic
liver samples. Further investigation of this lipid species may prove
it to be a useful biomarker of the disease as well. Another
significant observation was the increase of species containing
monounsaturated FA (mainly oleate, 18:1) in the diseased livers
when compared to controls (shown in Figure 2). This is likely
attributable to the excess saturated FA (due to diet or other factors)
and probably activation of desaturase enzymes (such as CSD1)
[23]. This change in the phospholipid FA composition could
possibly have an effect on the triacylglycerol synthesis from DAGs
via phosphatidate phosphohydrolase of PA [24].
Comparison of the changes in phospholipid species between
murine livers and diseased human livers show several strong
similarities. In particular, changes in species of PS and PI from
livers of mice maintained on a high fat diet are very similar to the
ones observed from human steatotic and cirrhotic specimens. The
observed increase in plasmalogen PC and PE in the diseased
samples compared to normal could reflect an accumulation in the
liver in contrast to the decreased levels of plasmalogen lipids in
plasma from NASH and NAFLD cases as a signature of
peroxisomal dysfunction [25].
Previous research has focused on the triglyceride accumulation
within the liver [26]. Triacylglycerol (TAG), free cholesterol, and
cholesterol esters have been reported as elevated as a result of
starvation-induced hepatic steatosis [27]. Lipid accumulation in
hepatocytes makes them more susceptible to injury by oxidative
stress and inflammatory cytokines, whose production in the liver is
triggered by the lipid peroxidation products [28,29]. TAG
synthesis (largely regulated by diacylglycerol acyl transferase
(DGAT)) protects hepatocytes from free fatty acid (FFA)
accumulation [30], thus making its precursor DAG an equally
important player.
The most striking changes noted in human and murine samples
of steatotic liver specimens were dramatic fold changes in DAG
species. A detailed identification of DAG species known to be
involved in fundamental intracellular signaling pathways could
help to elucidate mechanisms contributing to the progression of
NAFLD. Analysis of DAG species demonstrated an increase in
saturated and monounsaturated species in steatotic versus normal
human specimens, an effect which is more pronounced in the
murine data where the magnitude of these species’ fold changes
was greater (WD/control). Previous reports have connected DAG
signaling through protein kinase C (PKC) to processes important
in cancer progression [31–32]. Changes in specific DAG species
such as 38:4 have been shown to influence PKC activation and
consequently regulation of cell proliferation [33]. While this same
species of DAG did not demonstrate a large fold change over
controls in the steatotic group, many other species demonstrated
dramatic fold changes. Among these may be important regulators
of proliferation or apoptosis in NAFLD. In addition, specific DAG
transferases have been implicated in the progression of NAFLD
and liver fibrosis [34,35]. Modulation of DAG levels as well as
their altered fatty acid composition could greatly affect PKC and
Figure 7. Principal component analysis of murine lipidomics data. Murine samples for different diets (control, dots; Western diet=WD,
crosses). All replicates are shown.
doi:10.1371/journal.pone.0022775.g007
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perhaps the risk of malignancy in the setting of NAFLD. Previous
studies from our group have demonstrated an increase in
metastatic tumor burden in the liver in mice with steatotic livers
when compared to normal controls [14]. Thus, significant changes
in DAGs merit further study to understand their potential roles in
tumor initiation and early fibrotic changes in the liver microen-
vironment.
Not surprisingly, the human liver lipid profiles displayed higher
variability than mice maintained on a constrained diet (see error
bars in Figure 2). The agreement of the DAG changes between
human/murine data is substantial, but this is somewhat less true of
the glycerophospholipids. To the extent that humans and mice
demonstrate strong correlations between the diseased/normal and
WD/control lipid differences, in spite of the higher variability in
clinical specimens, it is indicative that the model presented here
can be used to further study mechanisms of NAFLD progression.
In conclusion, this report shows that lipidomics analysis based on
MS and computational algorithms is able to assess differences in
specific lipid composition in a highly dynamic system such as
NAFLD. We have identified upregulated lipid species that can be
further explored as potential targets for therapeutic intervention,
or which might demonstrate utility as biomarkers relevant to
reversible stages of NAFLD. Further work with specific candidate
lipids, notably among DAG species, could improve understanding
of signaling mechanisms involved in the progression of severe fatty
liver disease. In addition, by parallel analysis of murine liver tissues
we have shown that mice maintained on a high fat diet can be
used as a valuable model to study disease progression, and in the
future, to possibly evaluate treatment strategies and outcomes.
Based on these novel data, the roles of specific glycerophospholid
and DAG species in intracellular signaling, membrane composi-
tion, and other vital processes in early and late stage NAFLD can
be further examined in this complex disease process.
Supporting Information
Figure S1 Fragmentation spectra of m/z 871 peak. MS/MS
spectra of 38:4e PI from cirrhotic liver sample (eluting at
6.06 min).
(TIF)
Figure S2 MS/MS spectra of 18:0e/20:4 PI synthetic standard.
Fragmentation pattern of the liver sample PI yielded fragments
consistent with those appearing in the synthetic standard.
(TIF)
Table S1 Total number of identified phospholipid species in
each of the human liver (normal, steatotic, and cirrhotic) and
murine groups. The number includes the identification of isobaric
species (having the same total carbon number and number of
double bonds but presented in different fatty acids combinations.
I.e., 36:4 PC could be 16:0/20:4, 18:2/18:2, or 18:1/18:3), hence
the difference between number of identified phospholipid species
and number monitored in the MS scans.
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